$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
伏立诺他怎么样?
2025-10-19 11:44:20
Check Details
可泮利塞中国获批上市,治疗淋巴瘤总缓解率达59%!
2025-10-19 11:44:20
Check Details
伏立诺他的功效和作用?
2025-10-19 11:44:20
Check Details
苯达莫司汀哪里买便宜?
2025-10-19 11:44:20
Check Details
他泽司他用药效果怎么样
2025-10-19 11:44:20
Check Details
阿基仑赛“制胜”B细胞淋巴瘤——开启中国肿瘤CAR-T疗法新纪元
2025-10-19 11:44:20
Check Details
“靶向时代”Umbralisib治疗惰性淋巴瘤效果如何?总体缓解率高达47.1%!
2025-10-19 11:44:20
Check Details
利妥昔单抗适合膜性肾病吗?
2025-10-19 11:44:20
Check Details
利妥昔单抗靶向药的优缺点是什么?
2025-10-19 11:44:20
Check Details
利妥昔单抗使用后注意事项
2025-10-19 11:44:20
Check Details
利妥昔单抗的功效与副作用是怎样的
2025-10-19 11:44:20
Check Details
吉妥珠单抗白血病治疗效果怎么样
2025-10-19 11:44:20
Check Details
1
2
...
7351
7352
7353
7354
7355
7356
7357
...
10232
10233
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
2
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
3
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
4
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
5
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
6
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
7
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
8
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
9
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
10
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
11
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
12
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile